儿童免疫性血小板减少症血清中抗核仁抗体纯化以及靶抗原的筛选

免疫性血小板减少症为儿童常见获得性免疫性疾病,本研究前期发现有较高比例的抗核仁抗体阳性的儿童为免疫性血小板减少症患者。为筛选鉴定抗核仁抗体阳性免疫性血小板减少症患儿血清中抗核仁抗体识别的靶抗原,本研究利用HEP-2细胞系建立了细胞固定-抗体结合-抗体洗脱-抗体中和体系,成功纯化免疫性血小板减少症患儿血清中抗核仁抗体。利用蛋白免疫共沉淀和质谱分析法筛选出Ncl、Krt1、Krt2、Krt10等蛋白可能为免疫性血小板减少症患儿血清中抗核仁抗体结合的靶抗原。这些结果为免疫性血小板减少症患儿血清中抗核仁抗体靶抗原的鉴定提供有效方法,可进一步深化我们对免疫性血小板减少症发病机制的认识。     

痘病毒宿主范围因子及其作用机制研究进展

痘病毒是已知病毒中基因组最大、宿主谱最广和危害最严重的人兽共患病病原之一。随着病原和宿主互作的分子生物学、功能基因组学以及免疫学相关技术的发展,痘病毒宿主范围因子及其相关作用机制被相继发现和研究,这为痘病毒的组织嗜性和宿主特异性的阐明奠定了分子基础。本文将通过对脊椎动物重要痘病毒属主要成员的宿主范围因子及其作用机制的介绍,以加深对痘病毒的分子遗传演化、组织嗜性和跨宿主种间感染机制的理解和认识。     

首批人抗乙型脑炎病毒血清候选国家标准品的研制

目的 研制首批人抗乙型脑炎病毒血清候选国家标准品,用于乙型脑炎病毒中和抗体检测和乙型脑炎疫苗免疫效果评价。方法 采用乙型脑炎病毒中和抗体阳性的人血浆为原料,去除纤维蛋白原、灭活补体后分装冻干制成人源抗乙型脑炎病毒血清国家标准品。组织2家单位协作标定,并对候选标准品进行稳定性观察。结果 研制批号为201801人抗乙型脑炎病毒血清候选标准品共5 000余支;其外观、水分、无菌检查和分装精度等均符合《中华人民共和国药典》2020版(三部)要求。人源抗乙型脑炎病毒血清国家标准品中和抗体效价赋值为1∶123.8～1∶202.2,且在4℃保存3年中和抗体效价稳定。结论 该批人抗乙型脑炎病毒血清可作为国家标准品用于乙型脑炎疫苗临床血清中和抗体效价检测和乙型脑炎疫苗质量控制。     

鸡痘的诊断与防治技术研究

鸡痘是危害养鸡业发展的一种传染病,不分日龄大小均可发病,肉鸡和蛋鸡均可感染,发病期1-2周,雏鸡死亡率较高,可达5%～30%不等[1],近年来发病率和死亡率有上升趋势,并且免疫失败的病例时有发生[2].为了建立接种疫苗后抗体监测手段和研究感染鸡痘病毒后抗体产生规律,我们建立了间接ELISA检测鸡痘病毒抗体的方法,进一步做了中和试验和用阳性血清治疗鸡痘的试验,报告如下.     

ELISA 法用于马抗狂犬病毒抗体的检测

本文建立了ＥＬＩＳＡ间接法,用以检测精制（马）抗狂犬病血清（或血浆）制造过程中的中和抗体效价,并与传统的小鼠脑内中和法比较。结果表明（１）两种检测方法对不同水平抗体的检出是一致的。它们之间有很好的线性关系（ｙ＝２．１７ｘ＋２１,ｒ＝０．９９,ｐ＜０．０１）。（２）应用ＥＬＩＳＡ间接法测定马抗狂犬病血清效价简便、快速、特异性及重复性好,可代替小鼠脑内中和法。     

电压门控钠通道NaV1.7与痛信号的产生

电压门控钠通道NaV1.7选择性高表达在伤害感受性脊髓背根神经节的感觉神经元上,在疼痛电信号的产生、传导和调控中具有重要的生理功能。伤害性感受器上的NaV1.7亦在慢性神经痛和炎症痛的病理生理过程中发挥关键作用。近年来的研究发现,人类遗传性疼痛症(如红斑性肢痛病)与NaV1.7钠离子通道基因SCN9A的某些功能增强型突变相关。最近Cox等首次报道了SCN9A突变将导致人先天痛觉完全丧失,而无痛症患者机体其它功能正常,提示NaV1.7将可能成为有效治疗疼痛而无副作用的一个新靶标。     

发热伴血小板减少综合征患者血清内抗体IgG中和活性及其影响因素分析

发热伴血小板减少综合征(SFTS)的病原体为发热伴血小板减少综合征布尼亚病毒,目前尚无特异性防治措施。本研究旨在明确SFTS患者不同时期血清内抗体的中和活性,为将来开发单克隆中和抗体药物和疫苗设计提供可靠的血源。7名患者15份血清收集后采用protein A亲和纯化抗体,SDS-PAGE分析抗体的纯度和分子量大小,中和实验评估抗体的中和能力,结果发现7个患者15份血清中4个恢复期患者血清内抗体具有广谱中和能力,其余3个患者未产生中和抗体,所有患者急性期均未产生IgG中和抗体,产生中和抗体的个体内抗体的中和能力随病毒消长而发生改变。因此,机体感染后部分康复者建立了特异性体液免疫力。此外,SFTS患者年龄亦影响中和抗体的产生,高龄并不预示着免疫力逐渐丧失,推测个体差异决定了免疫力强弱。具有广谱中和能力的血源将为开发治疗SFTS的候选抗体药物以及疫苗设计提供可能。     

人源中和性抗甲型肝炎病毒抗体Fab段基因的序列分析及可溶性表达

在用噬菌体表面呈现系统获得人源抗甲型肝炎（甲肝）病毒中和发生基因工程Fab抗体的基础上,对所获得的4株中和性Fab抗体轻重链可变区进行了序列分析、可溶性表达及生物学特性鉴定。4株Fab抗体重链可变区拥有99％同源的核苷酸序列和相同的CDR区氨基酸序列,属于VHⅢ基因家族,而轻链可变区核苷酸序列同源性为95％和相似的CDR区氨基酸序列,属于VL5基因家族。这些重组抗体都能与人甲肝恢复期血清及具有中和活性的鼠抗甲肝克隆抗体产生竞争抑制反应,表明其针对甲肝癌病毒结构蛋白上的主要抗的决定簇。     

戊型肝炎病毒中和性单克隆抗体的鉴定

阻断实验发现。用戊型肝炎病毒(HEV)衣壳蛋白重组抗原制备的8株抗HEV单克隆抗体(mAb),分别识别3个构象表位和2个线性表位。用抗体捕获反转录PCR方法证实,其中识别2个构象表位的3个mAb可以直接捕获HEV颗粒,表明这2个表位位于HEV颗粒的外表面。识别这两个表位的mAbSCll和8H3均可中和HEV对恒河猴的致病性和感染性。rnAb8C11缩短排毒时间的效应较明显,而mAb8H3延迟机体抗HEV抗体阳转时间的效应较明显。二者的中和效应具有较明显的协同作用。中和单抗8C11、8H3对戊肝不同感染时期的血清均有显著阻断作用,Fab片段的阻断作用与完整抗体类似,表明这两个mAb对应的中和表位是HEV体液免疫应答的优势表位。     

1975年上海市郊流行性肌痛(胸痛)的病原学调查

1975年7—9月上海嘉定县和宝山县部分地区发生流行性肌痛(胸痛)暴发流行。从34例患者的肛拭、咽喉洗液和粪便标本中分离到26株柯萨奇(cox)B。病毒。9例患者的双份血清和3例患者的恢复期血清与新分离病毒的代表株(沪肌痛75—9)作了中和试验,结果袭明,9例患者的恢复期血清中和抗体滴度较急性期有四倍或四倍以上的增长,恢复期血清中和抗体几何均值比急性期高42倍,从而肯定造成本次流行的病原体是coxB。病毒。     

Genome sequence of erythromelalgia-related poxvirus identifies it as an ectromelia virus strain

Erythromelagia is a condition characterized by attacks of burning pain and inflammation in the extremeties. An epidemic form of this syndrome occurs in secondary students in rural China and a virus referred to as erythromelalgia-associated poxvirus (ERPV) was reported to have been recovered from throat swabs in 1987. Studies performed at the time suggested that ERPV belongs to the orthopoxvirus genus and has similarities with ectromelia virus, the causative agent of mousepox. We have determined the complete genome sequence of ERPV and demonstrated that it has 99.8% identity to the Naval strain of ectromelia virus and a slighly lower identity to the Moscow strain. Small DNA deletions in the Naval genome that are absent from ERPV may suggest that the sequenced strain of Naval was not the immediate progenitor of ERPV.     

Reexamination of the efficacy of vaccination against mousepox

Experiments were conducted to evaluate the efficacy of three strains of vaccinia virus, IHD-T, Lister and Wyeth, to immunize the BALB/cByJ mouse against infection with ectromelia virus. Mice vaccinated with any of the strains were protected for at least 12 weeks against clinically apparent disease when challenged with cage-mates infected with a virulent stain (NIH-79) of ectromelia virus. However, 4 to 8 weeks after vaccination mice were capable of transmitting virus to non-vaccinated cage-mates. The results are discussed within the context of the current practices for preventing and controlling ectromelia epizootics.     

Detection of mouse ectromelia virus using the heterologous rabbit antiserum conjugated with fluorescein isothiocyanate

A technique for direct determination of cells infected with mouse ectromelia virus was elaborated using the indirect immunofluorescence method and heterologous rabbit antiserum against vaccinia virus. The proposed method can be performed in laboratories with simple equipment and does not require special virological laboratory.     

Changes in antigenic properties of the p35 protein of vaccinia virus in various protein fractions of the virion with the use of monospecific antisera

Three monospecific antisera to the major 35 kD (p35) surface protein of vaccinia and ectromelia viruses have been obtained. Two of them are obtained to p35 protein isolated by electrophoresis in the presence of sodium dodecylsulfate from the protein fractions of vaccinia virus, soluble in NP40 and NP40 with dithiothreitol (NP40 and DTT-fractions). The third serum is obtained to NP40-fraction of ectromelia virus, containing practically only p35 protein. The obtained antisera were compared in the reactions with the different fractions of viral proteins in two versions of solid phase radioimmunoassay. The effect of such reagents as sodium dodecylsulfate, NP40, 2-mercaptoethanol, ethanol on the antigenic properties of p35 protein from vaccinia virus is discussed.     

Immunochemical analysis of the products of translation of mRNA hybridized with the left HindIII-A-Sa1-fragment of vaccinia virus DNA

The left HindIII-A-Sal fragment of the vaccinia virus DNA has been analyzed by the technique of mRNA hybridizational selection with the subsequent translation in cell-free protein-synthesizing system from the rabbit reticulocytes. The viral mRNA hybridizable with the fragment was shown to direct the synthesis of 12, 17, 27, 42, 70 kD polypeptides in the cell-free protein-synthesizing system. Each of 12 and 42 kD polypeptides was demonstrated to react specifically with antisera to structural p12 and p42 coat proteins. The structural coat proteins p12, p20, p42 of the vaccinia virus are concluded to be the products of the same viral gene.     

Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene.

With the aid of three monoclonal antibodies (MAbs), a glycoprotein specifically localized to the outer envelope of vaccinia virus was shown to be encoded by the A33R gene. These MAbs reacted with a glycosylated protein that migrated as 23- to 28-kDa and 55-kDa species under reducing and nonreducing conditions, respectively. The protein recognized by the three MAbs was synthesized by all 11 orthopoxviruses tested: eight strains of vaccinia virus (including modified vaccinia virus Ankara) and one strain each of cowpox, rabbitpox, and ectromelia viruses. The observation that the protein synthesized by ectromelia virus-infected cells reacted with only one of the three MAbs provided a means of mapping the gene encoding the glycoprotein. By transfecting vaccinia virus DNA into cells infected with ectromelia virus and assaying for MAb reactivity, we mapped the glycoprotein to the A33R open reading frame. The amino acid sequence and hydrophilicity plot predicted that the A33R gene product is a type II membrane protein with two asparagine-linked glycosylation sites. Triton X-114 partitioning experiments indicated that the A33R gene product is an integral membrane protein. The ectromelia virus homolog of the vaccinia virus A33R gene was sequenced, revealing 90% predicted amino acid identity. The vaccinia and variola virus homolog sequences predict 94% identical amino acids, the latter having one fewer internal amino acid. Electron microscopy revealed that the A33R gene product is expressed on the surface of extracellular enveloped virions but not on the intracellular mature form of virus. The conservation of this protein and its specific incorporation into viral envelopes suggest that it is important for virus dissemination.     

Intestinal Resistance in the Experimental Enteric Infection of Mice with a Mouse Adenovirus

The influence of cyclophosphamide (Cy) on the establishment and duration of the intestinal resistance against enteric infection with a mouse adenovirus, strain K87, was examined in inbred mice, strain DK1. When Cy (40 mg/kg/day) was administered to mice for 17 days from the time of virus challenge, a clear prolongation of viral growth and a delayed appearance of neutralizing (NT) antibody in the intestinal wall as well as in the serum were observed. When Cy (40 mg/kg/day, for 14 days) was administered after cessation of viral growth (4 to 6 weeks after virus challenge) and part of the mice were rechallenged with the virus, titers of NT antibody and immunoglobulins became significantly lower than those in control mice not treated with Cy, and regrowth of the virus was observed in eight out of twenty-five Cy-treated mice, regardless of the presence or absence of re-challenge. In this experiment, antibody titers in the intestinal contents of eight virus-positive mice were significantly lower than those of the remaining seventeen virus-negative mice. The time when the decrease of intestinal NT antibody was maximum coincided with the time of the maximal frequency of viral regrowth. It was discussed that these facts might present an evidence to support the idea that the intestinal resistance was acquired through local NT antibody belonging to IgA in the intestinal tract.     

Recombinant vaccinia virus induces neutralising antibodies in rabbits against Epstein-Barr virus membrane antigen gp340.

The Epstein-Barr virus membrane antigen gene gp340 was isolated, inserted into several strains of vaccinia virus and expressed under the control of a vaccinia virus promoter. The EBV-derived protein which was produced by the recombinant vaccinia viruses was heavily glycosylated, readily labelled with threonine, could be detected at the surface of infected cells and had a mol. wt. of approximately 340 kd, all of which are properties of the authentic gp340. Polyclonal rabbit antisera against gp340 and an EBV-neutralising anti-gp340 monoclonal antibody both recognised cells infected with the recombinant vaccinia viruses. Moreover, rabbits vaccinated with one of the recombinants produced antibodies that recognised EBV-containing lymphoblastoid cells and neutralised EBV.     

Evidence for Persistence of Ectromelia Virus in Inbred Mice,Recrudescence Following Immunosuppression and Transmission to Na?ve Mice

Orthopoxviruses (OPV), including variola, vaccinia, monkeypox, cowpox and ectromelia viruses cause acute infections in their hosts. With the exception of variola virus (VARV), the etiological agent of smallpox, other OPV have been reported to persist in a variety of animal species following natural or experimental infection. Despite the implications and significance for the ecology and epidemiology of diseases these viruses cause, those reports have never been thoroughly investigated. We used the mouse pathogen ectromelia virus (ECTV), the agent of mousepox and a close relative of VARV to investigate virus persistence in inbred mice. We provide evidence that ECTV causes a persistent infection in some susceptible strains of mice in which low levels of virus genomes were detected in various tissues late in infection. The bone marrow (BM) and blood appeared to be key sites of persistence. Contemporaneous with virus persistence, antiviral CD8 T cell responses were demonstrable over the entire 25-week study period, with a change in the immunodominance hierarchy evident during the first 3 weeks. Some virus-encoded host response modifiers were found to modulate virus persistence whereas host genes encoded by the NKC and MHC class I reduced the potential for persistence. When susceptible strains of mice that had apparently recovered from infection were subjected to sustained immunosuppression with cyclophosphamide (CTX), animals succumbed to mousepox with high titers of infectious virus in various organs. CTX treated index mice transmitted virus to, and caused disease in, co-housed naïve mice. The most surprising but significant finding was that immunosuppression of disease-resistant C57BL/6 mice several weeks after recovery from primary infection generated high titers of virus in multiple tissues. Resistant mice showed no evidence of a persistent infection. This is the strongest evidence that ECTV can persist in inbred mice, regardless of their resistance status.     

Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge

We evaluated four priming-boosting vaccine regimens for the highly pathogenic simian human immunodeficiency virus SHIV89.6P in Macaca nemestrina. Each regimen included gene gun delivery of a DNA vaccine expressing all SHIV89.6 genes plus Env gp160 of SHIV89.6P. Additional components were two recombinant vaccinia viruses, expressing SHIV89.6 Gag-Pol or Env gp160, and inactivated SHIV89.6 virus. We compared (i) DNA priming/DNA boosting, (ii) DNA priming/inactivated virus boosting, (iii) DNA priming/vaccinia virus boosting, and (iv) vaccinia virus priming/DNA boosting versus sham vaccines in groups of 6 macaques. Prechallenge antibody responses to Env and Gag were strongest in the groups that received vaccinia virus priming or boosting. Cellular immunity to SHIV89.6 peptides was measured by enzyme-linked immunospot assay; strong responses to Gag and Env were found in 9 of 12 vaccinia virus vaccinees and 1 of 6 DNA-primed/inactivated-virus-boosted animals. Vaccinated macaques were challenged intrarectally with 50 50% animal infectious doses of SHIV89.6P 3 weeks after the last immunization. All animals became infected. Five of six DNA-vaccinated and 5 of 6 DNA-primed/particle-boosted animals, as well as all 6 controls, experienced severe CD4(+)-T-cell loss in the first 3 weeks after infection. In contrast, DNA priming/vaccinia virus boosting and vaccinia virus priming/DNA boosting vaccines both protected animals from disease: 11 of 12 macaques had no loss of CD4(+) T cells or moderate declines. Virus loads in plasma at the set point were significantly lower in vaccinia virus-primed/DNA-boosted animals versus controls (P = 0.03). We conclude that multigene vaccines delivered by a combination of vaccinia virus and gene gun-delivered DNA were effective against SHIV89.6P viral challenge in M. nemestrina.